Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 6
---
 filings. See “Prospectus Summary––Implications of Being an Emerging Growth Company and a Smaller Reporting Company.”

Investing in our securities involves a high degree of risk. See the section entitled“ Risk Factors” beginning on page 7 of this prospectus for a discussion of risks that should be considered in connection with an investment in our securities.

|                                    |     |   | Per                          
 Share and accompanying April 
 2025 Warrant                 |     |   | Per                    
 Pre-Funded Warrant     
 and accompanying April 
 2025 Warrant           |     |   | Total |
|:-----------------------------------|:----|:--|:-----------------------------|:----|:--|:-----------------------|:----|:--|:------|
| Public offering price              |     | $ |                              |     | $ |                        |     | $ |       |
| Placement Agent fees(1)            |     | $ |                              |     | $ |                        |     | $ |       |
| Proceeds to us, before expenses(2) |     | $ |                              |     | $ |                        |     | $ |       |

| (1) | We                                                                                                                                    
 have agreed to pay the Placement Agent a total cash fee equal to 8.0% of the gross proceeds raised in this offering. We have also     
 agreed to reimburse the Placement Agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $120,000. 
 In addition, we have agreed to issue to the Placement Agent, or its designees, warrants (the “Placement Agent Warrants”)              
 to purchase a number of shares of our Common Stock equal to 3.0% of the aggregate number of shares of Common Stock and Pre-Funded     
 Warrants being offered at an exercise price equal to 110% of the combined public offering price per share of Common Stock             
 and accompanying April 2025 Warrant. We refer you to “Plan of Distribution” on page 90 of this prospectus for additional              
 information regarding Placement Agent compensation.                                                                                   |

| (2) | Because                                                                                                                                 
 there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual offering 
 amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total   
 maximum offering amounts set forth above. We refer you to “Plan of Distribution” for additional                                         
 information regarding Placement Agent compensation